Join to view full profile
302 W La Veta Ave Ste 202Orange, CA 92866
Phone+1 714-545-5550
Fax+1 714-545-5748
Dr. Alva is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (Irvine)Residency, Psychiatry, 1994 - 1998
Universidad Autonoma de GuadalajaraClass of 1990
Certifications & Licensure
CA State Medical License 1995 - 2027
TX State Medical License 2017 - 2026
American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
- A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease Start of enrollment: 2017 May 09
- Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type Start of enrollment: 2022 Nov 01
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Valbenazine improves quality of life, functionality, and movement severity in patients with tardive dyskinesia: findings from the KINECT-PRO™ study.Christoph U Correll, M Mercedes Perez-Rodriguez, Joseph P McEvoy, David V Sheehan, Gustavo Alva
CNS Spectrums. 2026-08-11 - 1 citationsAssessing symptom severity in patients with markedly treatment-resistant depression: Insights from the RECOVER trial.A John Rush, Harold A Sackeim, Ying-Chieh Lisa Lee, Charles R Conway, Scott T Aaronson
Journal of Affective Disorders. 2026-06-15 - 4 citationsDurability of the benefit of vagus nerve stimulation in markedly treatment-resistant major depression: a RECOVER trial report.Charles R Conway, Augustus John Rush, Scott T Aaronson, Mark T Bunker, Charles Gordon
The International Journal of Neuropsychopharmacology. 2026-01-06
Press Mentions
Regeneration Biomedical’s Cell Therapy Reduces Tau, Boosts Cognition in Alzheimer’s CasesMay 6th, 2025- (6-Month Paliperidone Palmitate), First and Only Twice-Yearly Treatment for Adults with SchizophreniaSeptember 1st, 2021
Dollars for Docs Mints a MillionaireMarch 11th, 2013
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
